Overview
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
Status:
Completed
Completed
Trial end date:
2017-08-03
2017-08-03
Target enrollment:
0
0
Participant gender:
All
All
Summary
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Noden Pharma
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- Successful completion of study CSPP100A2365E1
- Patients must meet inclusion criteria set forth for trials CSPP100A2365 and
CSPP100A2365E1
- Informed consent/ patient assent
Exclusion Criteria:
•Patients who did not successfully complete studies CSPP100A2365 and CSPP100A2365E1